文献速递乳腺癌放疗

评估乳腺癌患者术前放疗加量可行性的2期前瞻性临床试验主要结局的初步结果

First Results of the Primary Outcome of a Phase 2 Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Patients With Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-09-04

这项2期前瞻性试验纳入55例临床淋巴结阴性、适合保乳治疗的乳腺癌患者,术前给予肿瘤床放疗加量1332 cGy分4次,术后全乳放疗3663 cGy分11次。主要结局为3级及以上伤口并发症发生率不劣于术后标准全乳放疗加量(6%-20%),结果显示1例(2%)发生需手术修复的3级伤口裂开,靶区加量体积显著小于模拟术后体积(11 cc vs 56 cc,P < .001)。

要点

  • 术前放疗加量1332 cGy分4次后行肿块切除术及术后全乳放疗3663 cGy分11次。
  • 3级伤口并发症发生率为2%(1例需手术修复的伤口裂开),未劣于预设的6%-20%范围。
  • 靶区加量体积显著小于模拟术后体积(11 cc vs 56 cc,P < .001)。

核心结论

  • 按本方案行术前放疗加量后全乳放疗,主要结局可接受,术后伤口并发症发生率与标准术后放疗相似,且加量体积更小。
  • 该方法目前正被考虑用于合作组3期试验。

研究设计与样本

  • 前瞻性2期临床试验,于2021年6月至2022年10月入组55例临床淋巴结阴性、适合保乳治疗的乳腺癌患者。
  • 中位年龄64岁(范围40-77岁);43例浸润性癌,5例导管原位癌;中位临床肿瘤大小13 mm(范围5-26 mm)。

主要发现

  • 1例(2%)发生需手术修复的3级伤口裂开,无其他3级不良事件。
  • 3例(6%)发生需抗生素治疗的2级感染。
  • 靶区加量体积显著低于模拟术后体积(11 cc vs 56 cc,P < .001)。
  • 首次随访时美容结局很好或极好的患者占87%,无美容结局差者。

关键数值与推荐

  • 术前放疗加量为1332 cGy分4次,术后全乳放疗为3663 cGy分11次。
  • 主要结局预设3级及以上伤口并发症发生率不劣于肿块切除加标准术后全乳放疗加量的6%-20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A radiation therapy (RT) boost to the tumor bed is an important component of breast-conserving therapy in early breast cancer. This prospective phase 2 study assessed the feasibility of delivering the RT boost before surgery. We hypothesize wound complication rates to be comparable with postoperative RT and the target boost volume to be smaller than standard postoperative RT. METHODS AND MATERIALS: This prospective phase 2 trial accrued 55 patients with clinically node-negative breast cancer eligible for breast-conserving therapy. Patients were treated with preoperative RT boost of 1332 cGy in 4 fractions, followed by lumpectomy and postoperative adjuvant whole breast RT to 3663 cGy in 11 fractions. The primary outcome was to demonstrate the incidence of grade 3 or more wound complications was not inferior to lumpectomy with standard postoperative whole breast RT and boost (6%-20%). We also compared the preop boost volume with a mock boost volume that would have been done after surgery. RESULTS: Fifty-five women were enrolled between June 2021 and October 2022. Median age was 64 years old (range, 40-77 years). Forty-three patients had invasive cancers, and 5 had ductal carcinoma in situ. Median clinical tumor size was 13 mm (range, 5-26 mm). Grade 3 wound dehiscence requiring surgical revision occurred in 1 patient (2%). There were no other grade 3 adverse events. Three patients (6%) had grade 2 infections requiring antibiotics. The target boost volume was significantly lower than mock postoperative volume (11 cc vs 56 cc; P < .001) Cosmetic outcome at the first follow-up was very good or excellent in 87% of patients, and none had poor cosmetic outcomes. CONCLUSION: The use of a preoperative RT boost followed by whole breast RT as administered here resulted in an acceptable primary outcome with a similar rate of postoperative wound complications and smaller boost volume compared with standard postoperative RT. This approach is currently under consideration for cooperative group phase 3 trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yehia ZA, Sherwani Z, Chakraborty M, et al. First Results of the Primary Outcome of a Phase 2 Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Patients With Breast Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39241809. doi:10.1016/j.ijrobp.2024.08.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。